Compare Futu Holdings Ltd (FUTU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Tango Therapeutics Inc. — how do they compare? Futu Holdings Ltd trades at $107.08 (market cap $15.35B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Futu Holdings Ltd is far larger — about 4.1× Tango Therapeutics Inc.'s market cap, and Futu Holdings Ltd pays a 2.37% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Tango Therapeutics Inc. for 0 Days on average.
| FUTU | TNGX | |
|---|---|---|
Market Cap | $15.35B | $3.74B |
Volume | 1,329,666 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $199.04 | $32.90 |
52-Week Low | $89.76 | $7.50 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $15.69B | $2.76B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings trades at $114.06, up 1.6% today, with a neutral technical signal and bullish moving averages. Revenue surged to $22.85 billion in 2025, with a net income margin of 49.62%, while valuation ratios like a P/E of 11.38 appear attractive. Recent news highlights Moomoo's expansion and a class action lawsuit deadline.
The outlook is mixed: strong fundamentals and analyst upside targets near 33% support growth, but legal risks and a recent earnings miss pose headwinds. Investors should weigh robust profitability against regulatory and competitive pressures in the financial services sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
